Green Cross and POSCO Capital leads $13.5 mln round for Juventas Therapeutics

Cleveland-based Juventas Therapeutics, a biotech company that is developing non-viral gene therapies that treat advanced cardiovascular diseases, has raised $13.5 million in Series B-2 funding. Green Cross Holdings and POSCO Capital led the round. Also, Juventas has received $6 million in debt funding from Oxford Finance and may get $9 million more “if specific milestones are met.” In addition to the financing, Juventas has named James Boland, Ernst & Young‘s retired vice chairman, to its board of directors. Boland is also former president and CEO of the Cleveland Cavaliers.

Pritok Capital snags $12.4 mln from Oxford Finance

Pritok Capital, a private equity firm that invests in senior care real estate, has received a $12.4 million loan from Oxford Finance. Proceeds of the loan were used by Pritok to acquire two nursing facilities in Kansas and Missouri.

Oxford Finance, Square 1 provide $10 mln to Tarsa Therapeutics

Oxford Finance and Square 1 Bank have provided a $10 million senior credit facility to biopharmaceutical company Tarsa Therapeutics. The company plans to use the proceeds to help file a drug application with the U.S. Food and Drug Administration for medication to treat post-menopausal osteoporosis, targeted for early 2015. Tarsa also announced biopharmaceutical veteran Daniel Soland has joined the company’s board.

IntelliCyt grabs $4 mln from Oxford Finance

Specialty finance firm Oxford Finance has provided a $4 million debt facility to IntelliCyt Corp. The loan will be used for working capital, marketing and product development. Headquartered in Albuquerque, New Mexico, IntelliCyt develops high-throughput cell and bead-based screening solutions.

VC-backed Zafgen nabs $20 mln from Oxford and MidCap Financial

Zafgen has secured a $20 million loan from Oxford and MidCap Financial. Based in Cambridge, Mass., Zafgen is a biopharmaceutical company focused on treating severely obese patients. Zafgen’s investors include RA Capital Management, Brookside Capital, Venrock and Alta Partners.

Sonendo snags $10 mln from Oxford Finance

Sonendo said Monday that it has received $10 million in debt financing from Oxford Finance. Based in Laguna Hills, Calif., Sonendo is a provider of technologies for endodontic therapy. Its backers include OrbiMed Advisors, Themes Investment Partners, Fjord Ventures and NeoMed Management.

Molecular Diagnostics Co XDx Secures Debt Financing

Oxford Finance has announced a $15 million round of debt financing for XDx. Silicon Valley Bank acted as co-lender in this transaction. XDx is based in Brisbane, California and is a molecular diagnostics company. Proceeds of the loan will be used for working capital and to fund the development of new diagnostic applications.

Vitae Secures Debt Financing

Vitae Pharmaceuticals has secured a $15 million round of debt financing from Oxford Finance, a specialty finance firm that provides senior debt to life sciences and healthcare services companies and Silicon Valley Bank. The funds will be used to support the progress of Vitae’s drug pipeline, which includes treatments for chronic kidney disease, diabetes, Alzheimer’s […]

Radius Health Closes $91M Round

Radius Health Inc. said Tuesday that it closed a $91 million third round of financing. The round includes $66 million in equity financing, and a commitment by GE Capital, Healthcare Financial Services and Oxford Finance for a $25 million multi-draw term loan facility. Five new investors–including BB Biotech AG, Brookside Capital, Saints Capital, Nordic Bioscience, and Ipsen Pharma SAS–joined existing investors MPM Capital, BB Biotech Ventures, MPM Bio IV NVS Strategic Fund, The Wellcome Trust, HealthCare Ventures, and Scottish Widows Investment Partnership in the equity portion of the round. Radius Health is based in Cambridge, Mass. Radius also announced that immediately following the initial closing of the financing, it merged with MPM Acquisition Corp., an unlisted public reporting shell company. The combined company will go by the name Radius Health. Radius is a developer of drug therapies for osteoporosis and women’s health.

Oxford Finance Nets $460M

Oxford Finance, a company that makes loans to life science and healthcare companies, has raised $460 million from Sumitomo Corp. and private equity firm Welsh, Carson, Anderson & Stowe, Reuters reported. Oxford Finance has been majority-owned by Sumitomo since 2004. The company will use the new money, in part, to expand its portfolio.

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget